Incyte Genomics Inc (INCY)

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Industry: Services-Commercial Physical & Biological Research (SIC 8731)

Market region: US

Address: 1801 Augustine Cut-Off, Wilmington, DE, 19803

Market capitalization

24.54 billion USD (24,539,393,712 USD)

Listing date

11/03/1993

Weighted shares outstanding

203,832,492

Share class shares outstanding

202,697,746

https://www.incyte.com